Literature DB >> 33673050

The BIRC Family Genes Expression in Patients with Triple Negative Breast Cancer.

Anna Makuch-Kocka1, Janusz Kocki2, Anna Brzozowska3, Jacek Bogucki4, Przemysław Kołodziej5, Bartosz J Płachno6, Anna Bogucka-Kocka5.   

Abstract

The BIRC (baculoviral IAP repeat-containing; BIRC) family genes encode for Inhibitor of Apoptosis (IAP) proteins. The dysregulation of the expression levels of the genes in question in cancer tissue as compared to normal tissue suggests that the apoptosis process in cancer cells was disturbed, which may be associated with the development and chemoresistance of triple negative breast cancer (TNBC). In our study, we determined the expression level of eight genes from the BIRC family using the Real-Time PCR method in patients with TNBC and compared the obtained results with clinical data. Additionally, using bioinformatics tools (Ualcan and The Breast Cancer Gene-Expression Miner v4.5 (bc-GenExMiner v4.5)), we compared our data with the data in the Cancer Genome Atlas (TCGA) database. We observed diverse expression pattern among the studied genes in breast cancer tissue. Comparing the expression level of the studied genes with the clinical data, we found that in patients diagnosed with breast cancer under the age of 50, the expression levels of all studied genes were higher compared to patients diagnosed after the age of 50. We observed that in patients with invasion of neoplastic cells into lymphatic vessels and fat tissue, the expression levels of BIRC family genes were lower compared to patients in whom these features were not noted. Statistically significant differences in gene expression were also noted in patients classified into three groups depending on the basis of the Scarff-Bloom and Richardson (SBR) Grading System.

Entities:  

Keywords:  BIRC family genes; gene expression regulation; inhibitors of apoptosis proteins; triple negative breast cancer

Mesh:

Substances:

Year:  2021        PMID: 33673050      PMCID: PMC7918547          DOI: 10.3390/ijms22041820

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  78 in total

1.  Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.

Authors:  Dae-Kwang Kim; Carlos S Alvarado; Carlos R Abramowsky; Lubing Gu; Muxiang Zhou; Minn-Minn Soe; Kevin Sullivan; Bradley George; Erwin Schemankewitz; Harry W Findley
Journal:  Pediatr Dev Pathol       Date:  2005-11-18

2.  Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.

Authors:  Siyuan Zheng; Andrew D Cherniack; Ninad Dewal; Richard A Moffitt; Ludmila Danilova; Bradley A Murray; Antonio M Lerario; Tobias Else; Theo A Knijnenburg; Giovanni Ciriello; Seungchan Kim; Guillaume Assie; Olena Morozova; Rehan Akbani; Juliann Shih; Katherine A Hoadley; Toni K Choueiri; Jens Waldmann; Ozgur Mete; A Gordon Robertson; Hsin-Ta Wu; Benjamin J Raphael; Lina Shao; Matthew Meyerson; Michael J Demeure; Felix Beuschlein; Anthony J Gill; Stan B Sidhu; Madson Q Almeida; Maria C B V Fragoso; Leslie M Cope; Electron Kebebew; Mouhammed A Habra; Timothy G Whitsett; Kimberly J Bussey; William E Rainey; Sylvia L Asa; Jérôme Bertherat; Martin Fassnacht; David A Wheeler; Gary D Hammer; Thomas J Giordano; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

Review 3.  Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.

Authors:  Parham Khosravi-Shahi; Luis Cabezón-Gutiérrez; Sara Custodio-Cabello
Journal:  Asia Pac J Clin Oncol       Date:  2017-08-16       Impact factor: 2.601

4.  bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer.

Authors:  Pascal Jézéquel; Mario Campone; Wilfried Gouraud; Catherine Guérin-Charbonnel; Christophe Leux; Gabriel Ricolleau; Loïc Campion
Journal:  Breast Cancer Res Treat       Date:  2011-03-31       Impact factor: 4.872

5.  Overexpression of survivin initiates hematologic malignancies in vivo.

Authors:  S Small; G Keerthivasan; Z Huang; S Gurbuxani; J D Crispino
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

Review 6.  The inhibitors of apoptosis (IAPs) and their emerging role in cancer.

Authors:  E C LaCasse; S Baird; R G Korneluk; A E MacKenzie
Journal:  Oncogene       Date:  1998-12-24       Impact factor: 9.867

7.  The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs.

Authors:  Tencho Tenev; Katiuscia Bianchi; Maurice Darding; Meike Broemer; Claudia Langlais; Fredrik Wallberg; Anna Zachariou; Juanita Lopez; Marion MacFarlane; Kelvin Cain; Pascal Meier
Journal:  Mol Cell       Date:  2011-07-07       Impact factor: 17.970

Review 8.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

9.  Prognostic importance of survivin in breast cancer.

Authors:  S M Kennedy; L O'Driscoll; R Purcell; N Fitz-Simons; E W McDermott; A D Hill; N J O'Higgins; M Parkinson; R Linehan; M Clynes
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

10.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.

Authors:  Darshan S Chandrashekar; Bhuwan Bashel; Sai Akshaya Hodigere Balasubramanya; Chad J Creighton; Israel Ponce-Rodriguez; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally
Journal:  Neoplasia       Date:  2017-07-18       Impact factor: 5.715

View more
  2 in total

1.  The N6-Methylandenosine-Related Gene BIRC5 as a Prognostic Biomarker Correlated With Cell Migration and Immune Cell Infiltrates in Low Grade Glioma.

Authors:  Xiulin Jiang; Yulin Shi; Xi Chen; Haitao Xu; Xiaobin Huang; Lihua Li; Jun Pu
Journal:  Front Mol Biosci       Date:  2022-03-03

2.  Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.

Authors:  Anna Fäldt Beding; Peter Larsson; Khalil Helou; Zakaria Einbeigi; Toshima Z Parris
Journal:  BMC Cancer       Date:  2022-03-25       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.